Home » Stocks » RVNC

Revance Therapeutics, Inc. (RVNC)

Stock Price: $25.80 USD -0.26 (-1.00%)
Updated Mar 3, 2021 4:00 PM EST - Market closed
After-hours: $25.50 -0.30 (-1.16%) Mar 3, 7:30 PM
Market Cap 1.82B
Revenue (ttm) 15.33M
Net Income (ttm) -282.09M
Shares Out 58.01M
EPS (ttm) -4.86
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 3
Last Price $25.80
Previous Close $26.06
Change ($) -0.26
Change (%) -1.00%
Day's Open 26.13
Day's Range 25.52 - 26.65
Day's Volume 776,587
52-Week Range 11.78 - 34.62

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 week ago

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Participate in Upcoming Virtual Healthcare Conferences

GlobeNewsWire - 1 week ago

Dublin, Feb. 24, 2021 (GLOBE NEWSWIRE) -- The "Facial Injectable Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering. The facial injectable market ...

Other stocks mentioned: AGN
Business Wire - 1 week ago

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire - 1 week ago

SAN DIEGO--(BUSINESS WIRE)--Ambrx Appoints Audit Executive Chris Nolet to Board of Directors

Other stocks mentioned: PTE, VIE
Benzinga - 1 week ago

Revance Therapeutics Inc (NASDAQ: RVNC) has reported topline data from JUNIPER Phase 2 study evaluating DaxibotulinumtoxinA for Injection to treat adults with moderate to severe upper limb spa...

Benzinga - 1 week ago

Shares of Revance Therapeutics (NASDAQ:RVNC) increased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 25.25% year over year to ($1.24)...

Business Wire - 1 week ago

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Announces Positive Topline Phase 2 Data Supporting Advancement of DaxibotulinumtoxinA for Injection for the Treatment of ULS

Business Wire - 1 week ago

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Reports Fourth Quarter and Full Year 2020 Financial Results

Business Wire - 1 week ago

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Appoints Olivia C. Ware and Carey O'Connor Kolaja to Board of Directors

Benzinga - 1 week ago

On Monday, February 22, Revance Therapeutics (NASDAQ:RVNC) will release its latest earnings report. Benzinga's outlook for Revance Therapeutics is included in the following report.

Business Wire - 2 months ago

NASHVILLE, Tenn.--(BUSINESS WIRE)--Governor Lee, Commissioner Rolfe Announce Revance Therapeutics to Relocate Global Headquarters to Nashville

Zacks Investment Research - 3 months ago

Revance (RVNC) announces a delay in the FDA decision on its BLA for DaxibotulinumtoxinA for Injection due to COVID-19.

Seeking Alpha - 3 months ago

Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q3 2020 Results - Earnings Call Transcript

Benzinga - 3 months ago

Shares of Revance Therapeutics (NASDAQ:RVNC) decreased 8.62% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 39.58% year over year...

Zacks Investment Research - 3 months ago

Revance (RVNC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Investors Business Daily - 6 months ago

Revance Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. The post Stocks Showing Market Leadership: Revance Therapeutics Earns 93 RS Rati...

Seeking Alpha - 6 months ago

Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Revance Therapeutics (RVNC) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Seeking Alpha - 9 months ago

Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

As of late, it has definitely been a great time to be an investor in Revance Therapeutics.

Zacks Investment Research - 10 months ago

Revance (RVNC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 11 months ago

Investors need to pay close attention to Revance Therapeutics (RVNC) stock based on the movements in the options market lately.

Seeking Alpha - 1 year ago

Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q4 2019 Results - Earnings Call Transcript

The Motley Fool - 1 year ago

The company's frown line treatment moved closer to commercialization today.

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Revance Therapeutics.

Seeking Alpha - 1 year ago

Revance Therapeutics: A Robust Pick For 2020

The Motley Fool - 1 year ago

A new deal accelerates the company's shift to a commercial-stage biotech.

Seeking Alpha - 1 year ago

Revance Therapeutics: The Real Threat To Abbvie's Dividend

The Motley Fool - 1 year ago

Several companies raised capital on Wednesday.

Other stocks mentioned: DT, IMMU
The Motley Fool - 1 year ago

The pricing of a secondary offering is to blame.

Seeking Alpha - 1 year ago

Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q3 2019 Results - Earnings Call Transcript

Benzinga - 1 year ago

Earlier this month, Revance Therapeutics Inc (NASDAQ: RVNC) named Mark Foley as its new CEO.

The Motley Fool - 1 year ago

Possible merger and acquisition activity lifted one of these stocks.

Other stocks mentioned: HLT, VNET
Market Watch - 1 year ago

Biotech Revance Therapeutics Inc. RVNC, +4.46% said Monday it has named Mark J. Foley as chief executive, replacing Dan Browne who has stepped down due to a misjudgment in handling an employee...

Seeking Alpha - 1 year ago

Revance's DAXI seems to have a longer duration of effect than botox and its current competitors.

InvestorPlace - 1 year ago

These 10 monster growth stocks to buy all offer exciting opportunities. There's the important information for investors to keep in mind.

Other stocks mentioned: AERI, AMZN, CRM, CXO, DBX, FANG, NTNX, WIFI, YEXT
Seeking Alpha - 1 year ago

Revance Therapeutics, Inc. (RVNC) CEO Daniel Browne on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Revance (RVNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

Revance's share price has been battered over the past year.

Zacks Investment Research - 1 year ago

Revance Therapeutics (RVNC) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Seeking Alpha - 1 year ago

Revance Therapeutics, Inc. (RVNC) on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Revance (RVNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CNBC - 2 years ago

Revance Therapeutics CEO: Challenging Allergan

A new wrinkle to an old treatment helped the stock of Revance Therapeutics nearly double in 2017. Could its competitive streak against Allergan help push the company even higher? Jim Cramer as...

Other stocks mentioned: AGN

About RVNC

Revance Therapeutics, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI) which competed phase 3 clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; in phase 2 clinical trials to treat adult upper limb spasticity and plantar fasciitis, and in pre-clinical trials to treat chronic migraine. It ... [Read more...]

Industry
Biotechnology
IPO Date
Feb 6, 2014
CEO
Mark Foley
Employees
470
Stock Exchange
NASDAQ
Ticker Symbol
RVNC
Full Company Profile

Financial Performance

In 2020, RVNC's revenue was $15.33 million, an increase of 3,610.65% compared to the previous year's $413,000. Losses were -$282.09 million, 76.9% more than in 2019.

Financial Statements

Analyst Forecasts

According to 11 analysts, the average rating for RVNC stock is "Buy." The 12-month stock price forecast is 37.80, which is an increase of 46.51% from the latest price.

Price Target
$37.80
(46.51% upside)
Analyst Consensus: Buy